A US company will sell an unproven anti-ageing gene therapy abroad to skip the FDA

Biotech & Longevity 4 min 80 sources

Minicircle is about to offer a longevity gene therapy in Honduras, the Bahamas and Panama with no rigorous trials and no regulator's approval — while the field that plays by the rules saw real cures, real failures, and a pioneer go bankrupt.

Key takeaways

A US company is about to sell an unproven anti-ageing gene therapy in Honduras, the Bahamas and Panama specifically to bypass the FDA's testing rules.
The same week, the field that followed the rules delivered a real sickle-cell cure and an antifungal that passed its final trial — and watched a gene-editing pioneer go bankrupt.
Real longevity science is slow and unglamorous; the therapy on the waitlist sells the destination while skipping the journey that proves it's safe.

A longevity therapy built to dodge the gatekeeper

The lead story this week isn’t a trial result. It’s a business plan.

Minicircle, a company based in Austin, Texas, plans to start selling an injectable gene therapy it says will help people live longer [45]. A gene therapy is a treatment that puts new genetic instructions into your cells — here, instructions to make more of a protein called klotho, which is linked to slower ageing in animal studies [45]. The therapy has not been through rigorous clinical trials, and it has no approval from the US Food and Drug Administration, the agency that decides which medicines are safe and effective enough to sell, or from any other major regulator [45].

So the company is going where those rules don’t reach. To get around the years of testing the FDA requires, Minicircle will offer the treatment to people willing to travel to Honduras, the Bahamas or Panama [45]. It has opened a waitlist and says the therapy will be available within six months [45].

Klotho itself is a real protein with real science behind it — low levels track with faster ageing and disease in lab studies [45]. But “a protein matters in mice” and “an injection that boosts it is safe and works in people” are separated by exactly the testing being skipped. The whole point of a phase 3 trial — the large, final test that compares a treatment against a dummy in hundreds or thousands of people — is to find the harms and the disappointments that small studies miss. Skip it, and the person on the table becomes the trial.

The field that stayed inside the lines had a hard, honest week

It’s worth setting the bypass against what playing by the rules actually looked like this week — wins and losses, both real.

A man in Louisiana, Daniel Cressy, 23, became the first person in his region functionally cured of sickle cell disease through gene therapy [19]. Sickle cell is an inherited blood disorder that deforms red blood cells and causes brutal pain crises; “functionally cured” means the disease’s effects have effectively stopped, though long-term follow-up continues [19]. That is what an approved gene therapy delivers when the testing has been done.

The gene-editing company Intellia posted positive phase 3 data and its stock rose [32]. F2G and Shionogi said a new antifungal passed its phase 3 test and will head to regulators — antifungal drugs are a quietly urgent need, since dangerous fungal infections have few treatments [47].

And the failures landed in the same week. Sangamo, one of the early pioneers of gene editing, filed for Chapter 11 bankruptcy and agreed to sell its assets [16]. Passage Bio, spurned by the FDA, found its exit through a merger rather than a product [73]. A Pfizer lung-cancer drug fell short in its trial [74]; an Exelixis cancer drug missed its main goal [41]. This is the cost of the rules — slow, expensive, and full of dead ends. It is also why an approval means something.

Real longevity science is slow, and looks nothing like a waitlist

The contrast sharpens when you look at what ageing researchers are actually finding.

Scientists studying long-lived families — not individuals, whole families — are trying to tease out the genetic clues to a longer healthspan, the years lived free of chronic disease [10]. A separate study found that nearly half of adults over 65 measurably improved in physical or mental function over time, upending the assumption that ageing is only decline [24]. Researchers even turned to a tropical butterfly that barely ages — some Heliconius species live about three times longer than close relatives — hoping its biology hints at how decline slows in nature [30].

None of that is a product you can buy next month. It’s the unglamorous front end of science: find the mechanism, prove it, then — maybe, years later — make something. The longevity therapy on the waitlist sells the destination while skipping the journey.

Also moving

A few other threads worth holding. Eli Lilly quietly gave a single 79-year-old access to its powerful experimental obesity drug, retatrutide, through a “compassionate use” program — a route that lets one person get an unapproved drug outside a trial, raising questions about who gets exceptions and why [8][15]. An FDA panel weighed the first flu vaccine built on mRNA technology, the same approach behind the COVID shots [33]. And the WHO said Mapp and Gilead antivirals will be deployed in an Ebola trial in the Democratic Republic of Congo, where an outbreak is being fought [80].

The week’s quiet lesson runs underneath all of it: the difference between a treatment and a sale is the testing in between.

02 · Lesson · why it matters

The fence at the edge of the cliff

A barrier you resent is often the only thing standing between you and a risk you can't see — and the people who remove it rarely carry it.

A waitlist where a trial should be

A company in Texas is about to sell an injection it says will help you live longer. It hasn’t run the large trials that prove a medicine is safe. It doesn’t have a regulator’s approval. So it’s flying the treatment to clinics in Honduras, the Bahamas and Panama — countries where the rules it’s avoiding don’t reach.

That’s the whole move. The fence the FDA puts up isn’t there. So step around it.

It’s easy to read this as a story about one bold company and a slow agency. It’s really about something older and more useful: what a barrier is for, and what you quietly take on yourself the moment you climb over it.

The fence you can’t see the point of

There’s an old idea worth keeping: before you tear down a fence, find out why someone put it there. The fences that feel pointless are often the ones doing invisible work — holding back a harm that hasn’t happened to you yet, which is exactly why it feels like it never will.

A drug approval is a fence like that. From the outside it looks like delay — years of testing, mountains of paperwork, dead ends. The cost is loud and visible. The benefit is silent: the harms that didn’t reach you because someone made the treatment prove itself first. You never see the trial that caught the dangerous side effect, the disappointment that stopped a useless product before it shipped. You only feel the waiting.

This is the trap in every barrier we resent. The cost shows up on your side of the fence. The protection happens on the far side, where you can’t watch it work.

What a phase 3 trial is actually doing

Here’s the mechanism, plainly. A large final trial — a phase 3 — takes a treatment and gives it to hundreds or thousands of people, comparing it against a dummy, watching for years. Its real job isn’t to show the thing works. It’s to find the ways it doesn’t: the rare harm that only appears at scale, the benefit that shrinks to nothing under a fair test, the person it makes worse.

That work has to happen somewhere. It has to happen to someone. The entire design of the approval system is a decision about where that risk lands: on a monitored trial, with consent, doctors watching, the harm caught early and the rest of us protected by what it learns.

Skip the trial, and the risk doesn’t vanish. It just moves. It moves onto the individual buyer, alone, with no comparison group and no one collecting what goes wrong. The waitlist isn’t a shortcut around the testing. It is the testing — run one person at a time, in private, with no one taking notes.

Why we want the fence gone

None of this would work without the other half of the system: us. The pull to buy.

Wanting to live longer is not foolish. It’s one of the most human things there is. And that wish is what makes the fence feel like an enemy — because the barrier stands between you and the thing you most want to be true. A regulator weighing evidence is no match for the hope that this one might be real, that the slow scientists are just being timid, that the future is for sale and you could reach it first.

That’s the demand the bypass is built on. A company doesn’t fly an unproven injection to three countries because the science is ready. It does it because enough people want it to be true that they’ll travel, pay, and roll the dice with their own bodies. The fence isn’t only protecting us from the company. It’s protecting us from the part of ourselves that would rather hope than wait.

The trust you spend without noticing

There’s a wider web here, and you’re standing in it whether you buy anything or not.

When a medicine in your cabinet says “approved,” you don’t re-run the trials yourself. You can’t. You trust that a fence was there, that someone made the thing prove itself, that the word means what it says. That trust is infrastructure — invisible, load-bearing, holding up every ordinary decision you make about your health without a second thought.

Every product sold around the gatekeeper spends a little of that shared trust. It blurs the line between “tested” and “for sale.” It teaches people that the fence is optional, that approval is just bureaucracy, that the bold ones simply went around. And the cost of that blurring doesn’t land only on the buyers in Panama. It lands on the next person who can no longer tell, at a glance, whether the word “works” was earned or just printed.

The slow, expensive, frustrating fence is the reason any of us can trust the next bottle we open. None of us built it, most of us never think about it, and from inside the web it’s nearly impossible to see how much we lean on it — until someone shows us how easy it is to step around, and how little they’ll be standing nearby when it turns out the fence was holding something back.

03 · Lab · your turn

Around the Fence

Rehearse buying unproven longevity treatments and feel how skipping the trial moves the hidden risk onto you.

04 · Hope · carry this

The slow fence around medicine exists because people kept building it, caution by caution. The same week someone tried to step around it, that patient system handed a 23-year-old his life back, free of a disease he was born with.